Lei Lv, Dong Li, Di Zhao, Ruiting Lin, Yajing Chu, Heng Zhang, Zhengyu Zha, Ying Liu, Zi Li, Yanping Xu, Gang Wang, Yiran Huang, Yue Xiong, Kun-Liang Guan, Qun-Ying Lei*. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Molecular Cell. 2011;42(6):719-30.
Lei Lv#, Yan-Ping Xu#, Di Zhao, Fu-Long Li, Wei Wang, Naoya Sasaki, Ying Jiang, Xin Zhou, Ting-Ting Li, Kun-Liang Guan*, Qun-Ying Lei* and Yue Xiong*. Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization. Molecular Cell. 2013;52(3):340-52.
Tadashi Nakagawa#, Lei Lv#, Makiko NaKagawa, Yanbao Yu, Chao Yu, Ana C.D'Alessio, Keiko Nakayama, Heng-Yu Fan, Xian Chen and Yue Xiong*. CRL4VprBP E3 ligase promotes monoubiquitylation and chromatin binding of TET dioxygenases. Molecular Cell. 2015;57(2):247-60.
Lei Lv#, Qi Wang#, Yanping Xu#, Li-chung Tsao#, Tadashi Nakagawa, Haitao Guo, Lishan Su* and Yue Xiong*. Vpr targets TET2 for degradation by CRL4VprBP E3 ligase to sustain IL-6 expression and enhance HIV-1 replication. Molecular Cell. 2018;70(5):961-970.
Yan-ping Xu#, Lei Lv#, Ying Liu#, Matthew D. Smith, Wen-Cai Li, Xian-ming Tan, Meng Cheng, Zhijun Li, Michael Bovino, Jeffrey Aubé, and Yue Xiong*. Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy. Journal of Clinical Investigation. Journal of Clinical Investigation. 2019;129(10):4316–4331.
Ruonan Zhang, Yajing Yang, Wenjing Dong, Mingen Lin, Jing He, Xinchao Zhang, Tongguan Tian, Yunlong Yang, Kun Chen, Qun-Ying Lei, Song Zhang*, Yanping Xu*, Lei Lv*. D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1. Proceedings of the National Academy of Sciences of the United States of America. 2022;119(8):e2114851119; .
Xinchao Zhang, Shuyan Li, Jing He, Yun-jie Jin, Ruonan Zhang, Wenjing Dong, Mingen Lin, Yajing Yang, Tongguan Tian, Yuefan Zhou, Yixin Xu, Qun-Ying Lei, Jing Zhang, Qing Zhang, Yanping Xu*, Lei Lv*. TET2 suppresses VHL-deficiency-driven clear cell renal cell carcinoma by targeting HIF signaling. Cancer Research. 2022;canres. 3013.2021. doi: 10.1158/0008-5472.CAN-21-3013.
